Guardant Health's RADIOHEAD Study Validates Blood-Based Monitoring for Immunotherapy Response

Guardant Health announced the first clinical readout from its collaboration with the Parker Institute for Cancer Immunotherapy. The RADIOHEAD study found that the Guardant Reveal test successfully detected responses to immunotherapy across multiple solid tumor types in advanced-stage cancer patients. The study also showed that Guardant Reveal identified non-responders up to five months earlier than standard methods, supporting the use of blood-based monitoring to predict treatment response.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced the first clinical readout from its collaboration with the Parker Institute for Cancer Immunotherapy (PICI) in the RADIOHEAD study. The study, published in Cancer Research Communications, found that Guardant Reveal successfully detected responses to immunotherapy across multiple solid tumor types in advanced-stage cancer patients. Furthermore, Guardant Reveal identified non-responders up to five months earlier than standard methods, supporting the use of blood-based monitoring to predict treatment response [1].

The RADIOHEAD study analyzed over 500 patients with various advanced solid tumors, including lung, skin, head and neck, breast, GI, GU, and gynecologic cancers, receiving immunotherapy in a real-world setting. The study found that Guardant Reveal's ability to measure changes in tumor fraction at the molecular level provided significant insights into patient outcomes. Patients with a reduction in tumor fraction had improved outcomes, with a 75% lower risk of progression in those with at least an 80% decrease in tumor fraction [1].

Guardant Reveal's early detection capability could revolutionize cancer care by enabling oncologists to make more informed decisions faster. The study's findings support the use of blood-based monitoring to optimize treatment and improve patient outcomes [1].

This development comes as the global immune checkpoint inhibitors market is projected to reach $154.25 billion by 2030, driven by the rising prevalence of advanced cancers [2]. Tempus AI, Inc. (TEM), a competitor in the precision oncology space, recently introduced its xM for treatment response monitoring (TRM) assay, which also aims to detect molecular response to immunotherapy [2].

The results of the RADIOHEAD study underscore Guardant Health's commitment to transforming patient care and accelerating new cancer therapies through its advanced blood and tissue tests. The company's forward-looking statements, however, caution that actual results may differ materially from those anticipated [1].

References:
[1] https://finance.yahoo.com/news/radiohead-study-validates-guardant-reveal-120700965.html
[2] https://www.nasdaq.com/articles/tempus-ai-taps-growing-ici-market-new-xm-assay